{
  "RR": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T14:30:25Z",
      "headline": "White Diamond Research Posts On X \"We hired an investigator to check out $RR's bartender robot at the Walmart in Rockford, IL to see if it works. Seems clunky but functional for what it is. Disclosure: We don't have a position in RR right now.\"",
      "id": 43161075,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "RR"
      ],
      "updated_at": "2025-01-23T14:30:25Z",
      "url": "https://www.benzinga.com/news/25/01/43161075/white-diamond-research-posts-on-x-we-hired-an-investigator-to-check-out-rrs-bartender-robot-at-the-w",
      "added_at": "2025-01-24T12:45:10.998Z"
    }
  ],
  "TVGN": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T10:10:59Z",
      "headline": "Tevogen Bio On Thursday Reported On Its Recent Fireside Chat With Microsoft Discussing The  Future Of AI-Driven Drug Development During the J.P. Morgan Healthcare Conference",
      "id": 43185624,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "MSFT",
        "TVGN"
      ],
      "updated_at": "2025-01-24T10:11:00Z",
      "url": "https://www.benzinga.com/news/25/01/43185624/tevogen-bio-on-thursday-reported-on-its-recent-fireside-chat-with-microsoft-discussing-the-future-of",
      "added_at": "2025-01-24T12:45:13.545Z"
    }
  ],
  "NVNI": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T21:02:59Z",
      "headline": "Nuvini Receives Written Notice That It Regained Compliance With Nasdaq Minimum Bid Price Listing Requirements",
      "id": 43176317,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "NVNI"
      ],
      "updated_at": "2025-01-23T21:03:00Z",
      "url": "https://www.benzinga.com/news/25/01/43176317/nuvini-receives-written-notice-that-it-regained-compliance-with-nasdaq-minimum-bid-price-listing-req",
      "added_at": "2025-01-24T12:45:17.050Z"
    }
  ],
  "ELAB": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T13:07:48Z",
      "headline": "PMGC Subsidiary Northstrive Biosciences  To Present At Anti-Obesity Treatments Subsidiary",
      "id": 43189030,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ELAB"
      ],
      "updated_at": "2025-01-24T13:16:43Z",
      "url": "https://www.benzinga.com/general/biotech/25/01/43189030/pmgc-subsidiary-northstrive-biosciences-to-present-at-aanti-obesity-treatments-subsidiary",
      "added_at": "2025-01-24T13:25:37.106Z"
    }
  ],
  "HOTH": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T13:30:15Z",
      "headline": "Hoth Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement",
      "id": 43189483,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "HOTH"
      ],
      "updated_at": "2025-01-24T13:30:16Z",
      "url": "https://www.benzinga.com/general/25/01/43189483/hoth-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement",
      "added_at": "2025-01-24T13:32:28.788Z"
    }
  ],
  "FPH": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T21:12:05Z",
      "headline": "Five Point Holdings Q4 2024 GAAP EPS $0.65 Up From $0.39 YoY, Sales $159.786M Up From $118.759M YoY",
      "id": 43176805,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "FPH"
      ],
      "updated_at": "2025-01-23T21:12:06Z",
      "url": "https://www.benzinga.com/news/earnings/25/01/43176805/five-point-holdings-q4-2024-gaap-eps-0-65-up-from-0-39-yoy-sales-159-786m-up-from-118-759m-yoy",
      "added_at": "2025-01-24T14:12:14.291Z"
    }
  ],
  "AIFF": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T14:07:49Z",
      "headline": "Firefly Neuroscience Presents Studies Supporting FDA-Cleared BNA Platform For Drug Efficacy And Cognitive Change In Neuropharmacology And Psychiatry; Highlights Role In Brain Health Innovation.",
      "id": 43190535,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "AIFF"
      ],
      "updated_at": "2025-01-24T14:07:49Z",
      "url": "https://www.benzinga.com/general/biotech/25/01/43190535/firefly-neuroscience-presents-studies-supporting-fda-cleared-bna-platform-for-drug-efficacy-and-c",
      "added_at": "2025-01-24T14:14:11.474Z"
    }
  ],
  "NISN": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T14:16:12Z",
      "headline": "Nisun International Projects 2024 Revenue Of $300M-$350M, Net Income $11M-$15M, EPS $2.60-$3.60",
      "id": 43190738,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "NISN"
      ],
      "updated_at": "2025-01-24T14:16:12Z",
      "url": "https://www.benzinga.com/news/earnings/25/01/43190738/nisun-international-projects-2024-revenue-of-300m-350m-net-income-11m-15m-eps-2-60-3-60",
      "added_at": "2025-01-24T14:18:29.530Z"
    }
  ],
  "WKEY": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T14:21:26Z",
      "headline": "WISeKey And SEALSQ Announce AI Platform HUMAN-AI-T; Aims To Consolidate Global Human Wisdom And Preserve Knowledge; To Include Diverse Sources Like Religious, Legal, And Philosophical Texts",
      "id": 43190846,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "LAES",
        "WKEY"
      ],
      "updated_at": "2025-01-24T14:21:26Z",
      "url": "https://www.benzinga.com/news/25/01/43190846/wisekey-and-sealsq-announce-ai-platform-human-ai-t-aims-to-consolidate-global-human-wisdom-and-prese",
      "added_at": "2025-01-24T14:23:00.710Z"
    }
  ],
  "ALUR": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T20:50:13Z",
      "headline": "Allurion Announces Clinical Study Combining Allurion Program And GLP-1 Agonists To Improve Muscle Mass, Studies Show 5.6% Muscle Gain And 14% Weight Loss Over 4 Months With Allurion Balloon; In Another Study Of 167 Patients, Patients Treated With The Allurion Balloon Experienced A Weight Reduction Of 15.7% With No Change In Muscle Mass.",
      "id": 43175835,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ALUR"
      ],
      "updated_at": "2025-01-23T20:50:13Z",
      "url": "https://www.benzinga.com/general/biotech/25/01/43175835/allurion-announces-clinical-study-combining-allurion-program-and-glp-1-agonists-to-improve-muscle",
      "added_at": "2025-01-24T14:29:09.201Z"
    },
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-24T14:31:25Z",
      "headline": "Allurion Announces Securities Purchase Agreement For 1.24M Shares At $6 Each And Warrants For 1.24M Shares; Plans To Reprice July 2024 Warrants To $6 After Shareholder Approval, Raising ~$7.4M Of Gross Proceeds",
      "id": 43191194,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "ALUR"
      ],
      "updated_at": "2025-01-24T14:32:02Z",
      "url": "https://www.benzinga.com/news/25/01/43191194/allurion-announces-securities-purchase-agreement-for-1-24m-shares-at-6-each-and-warrants-for-1-24m-s",
      "added_at": "2025-01-24T14:32:43.411Z"
    }
  ],
  "VIGL": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T17:46:19Z",
      "headline": "HC Wainwright & Co. Reiterates Buy on Vigil Neuroscience, Maintains $17 Price Target",
      "id": 43169950,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "VIGL"
      ],
      "updated_at": "2025-01-23T17:46:19Z",
      "url": "https://www.benzinga.com/news/25/01/43169950/hc-wainwright-co-reiterates-buy-on-vigil-neuroscience-maintains-17-price-target",
      "added_at": "2025-01-24T14:50:11.126Z"
    },
    {
      "author": "Vandana Singh",
      "content": "",
      "created_at": "2025-01-23T16:33:18Z",
      "headline": "Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3",
      "id": 43167375,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/01/23/VIGL.png"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/01/23/VIGL.png"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/01/23/VIGL.png"
        }
      ],
      "source": "benzinga",
      "summary": "Vigil Neuroscience&#39;s VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer&#39;s treatment; Phase 2 begins Q3 2025.",
      "symbols": [
        "VIGL"
      ],
      "updated_at": "2025-01-23T16:33:18Z",
      "url": "https://www.benzinga.com/25/01/43167375/vigil-neurosciences-alzheimers-candidate-shows-encouraging-safety-profile-plans-to-start-mid-stage-study-in-q3",
      "added_at": "2025-01-24T14:50:11.126Z"
    }
  ],
  "DDD": [
    {
      "author": "Benzinga Newsdesk",
      "content": "",
      "created_at": "2025-01-23T21:20:17Z",
      "headline": "3D Systems And Daimler Buses Announce Solution For Remote Spare Part Printing",
      "id": 43177257,
      "images": [],
      "source": "benzinga",
      "summary": "",
      "symbols": [
        "DDD"
      ],
      "updated_at": "2025-01-23T21:20:17Z",
      "url": "https://www.benzinga.com/news/25/01/43177257/3d-systems-and-daimler-buses-announce-solution-for-remote-spare-part-printing",
      "added_at": "2025-01-24T14:55:54.782Z"
    }
  ],
  "EVTL": [
    {
      "author": "Avi Kapoor",
      "content": "",
      "created_at": "2025-01-23T17:06:44Z",
      "headline": "Dow Jumps 250 Points; American Airlines Issues Weak Outlook",
      "id": 43168544,
      "images": [
        {
          "size": "large",
          "url": "https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2025/01/23/2K4A2912.jpeg"
        },
        {
          "size": "small",
          "url": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2025/01/23/2K4A2912.jpeg"
        },
        {
          "size": "thumb",
          "url": "https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2025/01/23/2K4A2912.jpeg"
        }
      ],
      "source": "benzinga",
      "summary": " ",
      "symbols": [
        "AAL",
        "EA",
        "EVTL",
        "ICON",
        "LYTS",
        "TAL",
        "VNCE"
      ],
      "updated_at": "2025-01-23T17:06:45Z",
      "url": "https://www.benzinga.com/news/earnings/25/01/43168544/dow-jumps-250-points-american-airlines-issues-weak-outlook",
      "added_at": "2025-01-24T14:58:08.605Z"
    }
  ]
}